Slow drug delivery decreased total body clearance and altered bioavailability of immediate‐ and controlled‐release oxycodone formulations by Li, Yan et al.
This is the author manuscript accepted for publication and has undergone full peer review but has 
not been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as doi: 
10.1002/prp2.210 
This article is protected by copyright. All rights reserved 
 1 
Received Date : 25-Sep-2015 2 
Revised Date   : 01-Dec-2015 3 
Accepted Date : 09-Dec-2015 4 
Article type      : Original Article 5 
 6 
 7 
1. Title Page 8 
 9 
Slow Drug Delivery Decreased Total Body Clearance and Altered Bioavailability of Immediate and 10 















Celgene Corporation, 86 Morris Avenue, Summit, NJ 07920, USA 16 
Translational Development and Clinical Pharmacology 15 
2 
 18 
College of Pharmacy, the University of Michigan, Ann Arbor, MI 48109, USA 17 

















Li (Journal of Pharmacology Research & Perspectives ) Slow Delivery Decreased Clearance Altered 
Bioavailability (April, 2015) 
This article is protected by copyright. All rights reserved 
2. [Running title page]  22 
 23 
a) [Running title = 57 characters, max. 60 characters] Slow Delivery Decreased Clearance Altered 24 
Bioavailability 25 
 26 
b) Corresponding author: Simon Zhou, Translational Development and Clinical Pharmacology, Celgene 27 
Corporation, 86 Morris Avenue, Summit, NJ 07920, USA.  28 
E-mail address: szhou@celgene.com 29 
Phone number: 908-673-9284 30 
Fax: 908-673-2842 31 
 32 
c) Manuscript details:  33 
Number of text pages: 30 34 
Number of tables: 7 35 
Number of figures: 6 36 
Number of references: 36 37 
Word count in Abstract: 316 38 
Word count in Introduction: 475 39 
Word count in Discussion: 1039 40 
 41 















Li (Journal of Pharmacology Research & Perspectives ) Slow Delivery Decreased Clearance Altered 
Bioavailability (April, 2015) 
This article is protected by copyright. All rights reserved 
ADME, absorption, distribution, metabolism and excretion; AUC, area under the curve; BID, twice (two 43 
times) a day; CL, total body clearance; CL intrinsic, in vivo intrinsic clearance; Cmax, the maximum plasma 44 
concentration; CR, controlled-release; CYP, Cytochrome P450 enzymes; ER, extended-release; F, 45 
bioavailability; FOCEI, first-order conditional estimation with the INTERACTION; i.m., intramuscularly; 46 
i.n., intranasally; IR, immediate-release; i.v., intravenously; IV, intravenously; L/l, liter; NONMEM, 47 
nonlinear mixed effect model; OFV, objective function value; PK, pharmacokinetics; PO, orally; Q, inter-48 
compartment clearance; Qh
e) Recommended section assignment 53 
, the drug input rate into the blood flow feeding into clearance organ (portal 49 
liver blood flow for IV administration); QD, once a day; RV, residual variability; SE, standard error; s.c., 50 
subcutaneously; T1/2, terminal half life; USA, United States of America; V/F, apparent volume of 51 
distribution; VPC, visual predictive check  52 
Drug Discovery and Translational Medicine  54 
3. Abstract 55 
Oxycodone is a commonly used analgesic with a large body of pharmacokinetic data from various 56 
immediate-release or controlled-release formulations, under different administration routes, and in 57 
diverse populations.  Longer terminal half-lives from extravascular administration as compared to IV 58 
administration have been attributed to flip-flop pharmacokinetics with the rate constant of absorption 59 
slower than elimination.  However, PK parameters from the extravascular studies showed faster 60 
absorption than elimination.  Sustained release formulations guided by the flip-flop concept produced 61 
mixed outcomes in formulation development and clinical studies.  This research aims to develop a 62 
mechanistic knowledge of oxycodone ADME, and provide a consistent interpretation of diverging results 63 
and insight to guide further extended release development and optimize the clinical use of oxycodone. 64 
.PK data of oxycodone in human studies were collected from literature and digitized.  The PK data were 65 
analyzed using a new PK model with Weibull function to describe time varying drug releases/ oral 66 
absorption, and elimination dependent upon drug input to the portal vein.  The new and traditional PK 67 
models were coded in NONMEM.  Sensitivity analyses were conducted to address the relationship 68 
between rates of drug release/absorption and PK profiles plus terminal half-lives.  Traditional PK model 69 
could not be applied consistently to describe drug absorption and elimination of oxycodone. Errors were 70 
forced on absorption, elimination or both parameters when IV and PO profiles were fitted separately. 71 
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caused by slower absorption adequately describes the complex interplay between oxycodone 73 
absorption and elimination in vivo.  Terminal phase of oxycodone PK profile was shown to reflect slower 74 
total body drug clearance due to slower drug release/absorption from oral formulations,  Mechanistic 75 
PK models with Weibull absorption functions and release rate-dependent saturable total body clearance 76 
well described the diverging oxycodone absorption and elimination kinetics in the literature.  It showed 77 
no actual drug absorption during the terminal phase but slower drug clearance caused by slower 78 
release/absorption producing the appearance of flip-flop and offered new insight for the development 79 
of modified release formulations and clinical use of oxycodone. 80 
Keywords: Oxycodone, formulation, slow delivery, absorption, decreased clearance 81 
4. Introduction  82 
Oxycodone (14-hydroxy-7,8-dihydrocodeinone) is one of the most studied and widely used analgesics(FB 83 
and MT., 1997; MT, 2008).  It has been administered intravenously (i.v.) (Hao et al., 2014; Kokubun et 84 
al., 2014; Takala et al., 1997; Kokki et al., 2004), intramuscularly (i.m.) (Kokki et al., 2004),  intranasally 85 
(i.n.) (Takala et al., 1997; Dale et al., 2002),  subcutaneously (s.c.) (Kokubun et al., 2014) , bucally(Kokki 86 
et al., 2004), rectally(Li et al., 2011; Tegon et al., 2009), epidurally(Kokki et al., 2014), and orally (Bass et 87 
al., 2012; Kim et al., 2015; Mundin et al., 2012; Mandema et al., 1996) using immediate release solutions 88 
and immediate- and controlled-release tablets to diverse disease populations for the treatment of 89 
acute, and chronic non-malignant pain and cancer pain (Lux et al., 2014; Mehta et al., 2014; Poelaert et 90 
al., 2015; Stessel et al., 2014; Hanks et al., 2001; Radbruch and Nauck, 2002).   91 
Oxycodone has been shown to have consistent pharmacokinetic properties and pharmacologic activities 92 
in diverse ethnic populations of Caucasians, Japanese and Chinese(Hao et al., 2014; Kokubun et al., 93 
2014). Oxycodone is relatively well absorbed after oral administration, and commercially available IR 94 
and ER formulations have a bioavailability of 40–80%(Bass et al., 2012; Kim et al., 2015; Mundin et al., 95 
2012; Mandema et al., 1996).  The sublingual bioavailability of oxycodone is less than 20% at normal pH 96 
(Al-Ghananeem et al., 2006). The mean bioavailability of intranasal oxycodone is 46% but there is wide 97 
interindividual variability from 16% to 100% (Lofwall et al., 2012).  Approximately 40% of oxycodone is 98 
bound to plasma proteins in vitro (Vallejo et al., 2011). Approximately 99% of oxycodone is distributed 99 
outside the plasma compartment, as reflected by the large volume of distribution of oxycodone (2–3 100 
L/kg). The main known metabolic pathways of oxycodone are through O-demethylation to 101 
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2011; Naito et al., 2013; Soderberg Lofdal et al., 2013; Lalovic et al., 2006).  Oxycodone itself is the major 103 
contributor to the analgesic effect following oxycodone administration. Although two of the 104 
metabolites, in particular oxymorphone, have higher affinities for the μ-receptors, their contribution to 105 
the overall analgesic effect is insignificant (Trescot et al., 2008). Total plasma clearance of oxycodone in 106 
adults is 0.7–1 l/min, which is consistent with intermediate hepatic extraction and a moderate first-pass 107 
effect. The T1/2 is about 2–3 hours after i.v. administration, about 3 hours after immediate release (IR) 108 
solution and about 8 hours after controlled-release (CR) oxycodone (Bass et al., 2012; Mandema et al., 109 
1996; Kokki et al., 2004). 110 
Though a large body of pharmacokinetics data have been accumulated and effectively advanced the 111 
knowledge of pharmacokinetic disposition of oxycodone, gaps remain in the explanation of the 112 
diverging pharmacokinetic parameter values derived from IV and PO administration of oxycodone 113 
solutions, and between distinct PK parameters derived from oral administration of IR and ER 114 
formulations.  Among these, one particular problem stands out on how to correctly disentangle 115 
oxycodone oral absorption from its elimination.  Compared to IV administration, longer half-lives of 116 
oxycodone following PO administration has been attributed to flip-flop kinetics in which the rate of 117 
oxycodone oral absorption is slower than that of elimination, however, PK parameters derived from IR 118 
and ER pharmacokinetic profiles showed the absorption rate constant is much faster than the 119 
elimination rate constant contradicting the traditional concept of flip-flop kinetics.  In addition, the 120 
pharmacokinetic parameters by traditional non-compartment and compartment modeling from IV and 121 
various PO administrations varied significantly and sometimes were against common pharmacological 122 
understanding (especially discordant apparent volume of distribution and apparent total body 123 
clearance). Furthermore, guided by the flip-flop concept, efforts to slow oxycodone release, which have 124 
been the mainstay for BID and QD sustained release formulations, produced somewhat mixed outcomes 125 
in formulations development and clinical studies (Bass et al., 2012; Kim et al., 2015; Mundin et al., 2012; 126 
Mandema et al., 1996).  The purpose of this investigation is to survey the existing literature and develop 127 
a consistent mechanistic model for the divergent pharmacokinetics of oxycodone after IV and PO 128 
administration of IR and ER formulations; and provides new insight into oxycodone disposition and a 129 
consistent framework of oxycodone ADME to guide further extended release development and optimize 130 
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5. Methods 133 
Plasma oxycodone concentration-time data were obtained from 8 manuscripts(Bass et al., 2012; Hao et 135 
al., 2014; Kim et al., 2015; Kokubun et al., 2014; Mundin et al., 2012; Mandema et al., 1996; Takala et al., 136 
1997; Kokki et al., 2004).  The data covered a wide dose range from 5 mg to 20 mg following IV and 137 
extravascular administration using immediate and modified release formulations under fasted and fed 138 
conditions. 
Oxycodone Plasma-Concentration Time Data 134 
Table 1 summarizes the doses, types of formulations and routes of administration for each 139 
study. 140 
All the manuscripts were either obtained in digital pdf format or scanned from paper copies into pdf 141 
formatted files.  The electronic plasma-concentration time profile were then digitized using UN-SCAN-IT 142 
Graph Digitizing Software version 6.0 (Silk Scientific Inc., Orem, Utah, USA) software to obtain the 143 
plasma concentration and time data.   144 
Plasma concentration-time data of oxycodone were analyzed using non-compartmental PK methodology 146 
with Phoenix WinNonlin (CERTARA, Princeton, NJ, USA).  The Cmax was the highest concentrations 147 
based on the plasma concentration-time data, while the AUC were calculated using trapezoidal rules.  148 
PK parameters of V/F, CL/F, T1/2 and etc. were estimated based on the standard non-parametric 149 
methodology in WinNonlin. 150 
Non-Compartmental PK Analyses 145 
Compartmental model PK analyses were performed in NONMEM, version 7.2 (ICON Development 152 
Solutions, MD, US).  One-compartment model was parameterized in Ka, CL and V using ADVAN2, 153 
TRANS2 routine, while two-compartment model was parameterized in Ka, CL, Q, V2 and V3 using 154 
ADVAN4 and TRANS4 routine in NONMEM. 155 
Compartmental PK Analyses 151 
Weibull function is frequently applied to the analysis of dissolution and release studies of drug 156 
formulations(Gomez-Mantilla et al., 2013; Gomez-Mantilla et al., 2014; Tan et al., 2013).  The success of 157 
Weibull functions in describing drug release from oral formulations have been shown to capture 158 
concentration gradients near the releasing boundaries of the Euclidian matrix (Kosmidis and Argyrakis, 159 
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of the dissolution environment.  In addition, due to its versatile and flexible forms, Weibull function has 161 
been used numerically to describe complex plasma concentration-time profiles of oral absorption of 162 
drugs (VK, 1987; Zhou, 2003).  To describe the convex ascending oxycodone plasma concentration-time 163 
profile prior to Cmax, a time-varying Weibull function was introduced to describe time-varying 164 
absorption rate constant as follows: 165 
                                                    (1) 166 
The absorption rate defined by Weibull absorption were coded in NONMEM as follows: 167 
ALPHA=THETA(1)*EXP(ETA(1)) ;where θ1 is the rate constants (λ) of Weibull distribution 168 
BETA=THETA(2)*EXP(ETA(2)) ;where θ2 is the Weibull shape (κ) of Weibull distribution 169 
KA=BETA/ALPHA*(TIME/ALPHA)**(BETA-1)*EXP(-1*(TIME/ALPHA)**BETA) 170 
Though it not easy to ascribe physical interpretation of the Weibull shape (k) and rate constants (lamda), 171 
one can draw analogy of drug release as a function changing with time (such as release rate increases, 172 
decreases or not change with time) and also associated with a shape distribution.      173 
The concept that total body drug clearance is function of its intrinsic clearance rate and blood flow 174 
delivering drug to the clearance organ was first introduced by Pang and Rowland (KS and M., 1977) using 175 
the well-stirred tank model as: 176 
                                                                                                    (2) 177 
Whereas CL is the observed total body clearance, CL intrinsic is the intrinsic clearance defined as Vm/Km of 178 
metabolic rate of Michaelis-Menten kinetics, Qh is the drug input rate into the blood flow feeding into 179 
clearance organ (portal liver blood flow for IV administration for metabolism).   Total body clearance as 180 
defined by Equation 2 has been successfully applied to classify drugs into two categories of high and low 181 
extraction ratios.  And it has been shown in theory and practice that total body clearance of drugs with 182 
high extraction ratio is limited by the rate of blood flow feeding into the clearance organ of liver or 183 
kidney, while the total body clearance of drugs with low extraction ratio is determined by its intrinsic 184 
clearance.  As for drugs with mild to moderate intrinsic clearance, its total body clearance is defined by 185 
equation 2.   For intravenously administered oxycodone, CL intrinsic of oxycodone can be estimated based 186 
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administered orally in IR or ER formulations, the drug release rates from the formulations may be slower 188 
than rate of portal liver blood flow and thus reduce the drug input rate to liver. Therefore, the total 189 
body clearance for orally administered oxycodone would be determined by the drug release rate from 190 
the IR or ER formulations and the intrinsic oxycodone clearance defined by equation 2. 191 
Since there is no reason to suppose route of oxycodone administration would change its intrinsic 192 
distribution and clearance properties, simultaneous fitting of oxycodone plasma concentration-time 193 
profile following IV administration and PO administration of IR and ER formulations were performed 194 
using a single set of PK parameters of intrinsic oxycodone clearance, oxycodone volume of distribution 195 
and rate of distribution.  The absorption related PK parameters of bioavailability (F), first order 196 
absorption rate constant or time-varying Weibull absorption rate constants and formulation dependent 197 
drug release rate Qh
To assess the robustness of parameter estimates of absorption related oxycodone PK characteristics, PK 200 
analyses were conducted using plasma concentration-time data following PO administration of IR and 201 
ER formulations without data from IV administration.  In addition, the model developed using the data 202 
from IV administration and PO administration of IR and ER formulations were used to analyze separate 203 
oxycodone PK data from separate source modified release efforts. 204 
 were estimated based on the oxycodone plasma concentration-time data following 198 
IR or ER administration. 199 
Comparison of structural models was based on the objective function value (OFV) and goodness-of-fit 205 
criteria. A value of P < .001, representing a decrease in OFV of > 10.83, was considered statistically 206 
significant. Selection criteria during the model development process were based on goodness-of-fit 207 
plots, changes in the OFV, residual distributions, and parameter estimates and their relative SE values. 208 
 209 
6. Results  210 
Mean plasma concentration-time data of oxycodone following oral administration of immediate and 212 
sustained release formulations at 5 to 20 mg and intranasal administration at 6.7 mg were shown in 213 
Figure 1.  After reaching the peak concentration of Cmax, the oxycodone plasma concentrations 214 
followed a mono-exponential decline.  The terminal phases of the plasma concentration-time profiles 215 
had distinct half-lives with PO administration of immediate-release (IR) and controlled-release (CR) or 216 
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with intranasal administration.  These data were analyzed using non-compartmental and traditional 217 
compartmental analyses by way of one-compartment model with first order rate constants.  The results 218 
from non-compartmental and traditional compartmental analyses were tabulated in Table 2 and 219 
Table 3, together with the PK parameter values reported from the original manuscripts.   220 
Consistent with original literature, both non-compartmental and compartmental analyses for different 221 
doses and formulations resulted in significantly distinct sets of PK parameters. Though PK profiles were 222 
adequately described by different set of PK parameters, it is difficult to relate the PK parameters to the 223 
underlying ADME processes.  The wide range of apparent volume distribution from 397.43 liters to 224 
1415.98 liters based on non-compartmental analysis or from 28.1 liters to 1521 liters based on one-225 
compartment analysis, and relatively narrow range of apparent total body clearance from 74 to 120 L/hr 226 
suggested disproportional effect on oxycodone intrinsic distribution and intrinsic elimination parameters 227 
(ratio of apparent volume of distribution and apparent clearance (CL/F)/(V/F) = CL/V should be 228 
consistent regardless of F).  It is particularly perplexing that different route of drug delivery and different 229 
rate of oral delivery from IR to ER would change the intrinsic distribution and elimination of oxycodone, 230 
against the common pharmacology understanding that drug distribution and elimination are intrinsic to 231 
the molecule and agnostic to the path on which it arrives the blood circulation. 232 
 233 
Plasma concentration-time data following intravenous administration of oxycodone at 2.5, 5 and 10 mg 236 
in Chinese; at 5 mg in Japanese; at 0.05 mg/kg in adult Caucasians; and at 0.1 mg/kg in Caucasian 237 
Children from studies 1, 3, 5 and 6 (Hao et al., 2014; Kokubun et al., 2014; Takala et al., 1997; Kokki et 238 
al., 2004) and goodness-of-fit of the two-compartment analyses of the IV data to assess the intrinsic 239 
oxycodone distribution and clearance.  Solid lines: observed data; dotted lines: model predicted data 240 
were shown in Figure 2.  The IV oxycodone PK profiles followed a bi-phasic decline and were adequately 241 
described by a two-compartment structure model, and a single set of intrinsic PK parameters across a 242 
wide dose range in diverse populations (
Two-Compartment Analyses of the IV Data to Assess the Intrinsic Oxycodone Distribution and Total 234 
Body Clearance  235 
Table 4).    Consistent with known oxycodone ADME 243 
characteristics, larger volume of distribution from peripheral compartment as compared to volume of 244 
distribution from central compartment (105 versus 39.2 liters) and larger inter-compartment clearance 245 
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extensively distributed into tissue following intravenous administration.  In addition, high in vivo intrinsic 247 
clearance (CL intrinsic) of 75.8 liters/hours estimated from the modeling is consistent with its moderate 248 
hepatic extraction and first-pass effect. 249 
The plasma concentration-time data following both IV and PO administration of oxycodone IR and CR 252 
formulations from studies 2 and 8 (Kim et al., 2015; Mandema et al., 1996) were analyzed 253 
simultaneously using a two-compartment model with first order absorption rate constant and saturable 254 
elimination affected by slower drug input to portal vein defined by Equation 2 and common set of PK 255 
parameters on oxycodone distribution.  The results from the analyses were shown in 
 Two-Compartment Analyses with First-Order Absorption Rate Constant and Saturable Elimination 250 
Affected by Slower Drug Input to Portal Vein  251 
Table 5, and the 256 
goodness of fit of the model was shown in Figure 3. 257 
As shown in Figure 3, the model with input rate dependent clearance provided good fit of both the 258 
absorption and the terminal phases of IV and PO profiles of IR and CR formulations with distinct half-259 
lives. 260 
The plasma concentration-time data following both IV and PO administration of oxycodone IR 263 
formulations from study 4 (Bass et al., 2012) were initially analyzed simultaneously using a two-264 
compartment model with first-order absorption rate constant and saturable elimination affected by 265 
slower drug input to portal vein (Figure 4).  The model provided good fit of the terminal phases of IV and 266 
PO profiles. However, this model didn’t well characterize the absorption phases of different 267 
formulations.  A time varying Weibull function was introduced to describe time-varying profiles.  The 268 
results from the analyses were shown in 
Two-Compartment Analyses with Weibull Absorption and Saturable Total Body Elimination Affected 261 
by Slower Drug Input to Portal Vein  262 
Table 6, and the goodness of fit of the model was shown in 269 
Figure 4. 270 
As shown in Figure 4, the model with Weibull distribution improved the model fit during the absorption 271 
phase of oxycodone PK profile over the constant rate of absorption, while input rate dependent-total 272 
body clearance provided good fit of the terminal phase of IV and PO profiles of IR and CR formulation 273 
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The oxycodone plasma concentration following intranasal administration from study 5 (Takala et al., 277 
1997) (shown in Figure 1) were analyzed using a two-compartment model with Weibull absorption and 278 
saturable elimination affected by slower drug input to portal vein and common set of PK parameters on 279 
oxycodone distribution based on IV data.  The results from the analyses were shown in 
Two-Compartment Analyses with Weibull Absorption and Saturable Elimination Affected by Slower 275 
Drug Input to Portal Vein under Intranasal Administration 276 
Table 6, and the 280 
goodness of fit of the model was shown in Figure 5.  Again, the model provided good fit of both the 281 
intranasal absorption and the terminal phase of intranasal PK profile. 282 
The robustness of Weibull absorption and saturable elimination affected by slower drug input into 285 
portal vein was further assessed using the plasma concentration-time data following PO administration 286 
of oxycodone IR and ER formulations in the absence of the IV data.  In lieu of oxycodone PK profile 287 
following IV administration, visual inspection of the semi-log oxycodone concentration-time profile 288 
following PO administration of IR and ER formulations suggested a one-compartment model is adequate 289 
to describe the oxycodone plasma-concentration time profile.  Thus, the oral oxycodone PK profiles 290 
from study 2 (Mandema et al., 1996) were analyzed simultaneously using a one -compartment model 291 
with a first order absorption rate and saturable elimination affected by slower drug input to portal vein 292 
and common set of PK parameters on oxycodone distribution.  The results from the analyses were 293 
shown in 
Sensitivity Analysis using One-Compartment Analyses with Saturable Elimination Affected by Slower 283 
Drug Input to Portal Vein in the Absence of IV Data  284 
Table 7, and the goodness of fit of the model was shown in Figure 6. 294 
As shown in Figure 6, the model with input rate dependent total body clearance provided good model fit 295 
of orally administered oxycodone PK profile.  The results derived from the oral data without IV data 296 
were similar to those derived with both IV and oral data.  Further, though the apparent volume of 297 
distribution following IR administration has increased due to confounding F, the magnitude of change in 298 
V/F and apparent total body clearance CL/F following ER administration was 40% and 18%, respectively, 299 
tracking the 38% and 14% change estimated from with the IV data.  In addition, the model developed 300 
based on oxycodone IV and PO administration of IR and ER formulations provided adequate fit of 301 
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7. Discussion  304 
 Oxycodone is a drug with moderately high total body clearance of ~34-47 L/hr (in comparison of 86L/h 305 
liver blood flow) following a bolus IV dose (Kalso, 2005).  Interestingly, when oxycodone was 306 
administered in a slow intravenous infusion of ~ 1 mg/hour to Japanese patients, its total body 307 
clearance decreased from ~34 L/hr following a bolus intravenous injection to 24.3 L/hr indicating that 308 
oxycodone total body clearance following intravenous administration is sensitive to its input rate to 309 
blood (Kokubun et al., 2014).  Assuming a typical liver blood flow of 86L/hr, the intrinsic hepatic 310 
clearance of oxycodone is estimated to be 76 L/hr using equation 2.  With these typical values, slower 311 
intravenous infusion regimen may be designed to exploit the decrease oxycodone total body clearance 312 
with slow infusion rate to maximize the oxycodone plasma exposure and associated benefit and 313 
outcome for patients under intensive care in clinics.  314 
 Though intravenously administered bolus oxycodone behaved consistently across wide dose ranges and 315 
in diverse populations with dose proportional exposure and consistent distribution and elimination 316 
characteristics (Table 2 in results), there is considerable variability in oral oxycodone bioavailability 317 
reported in the literature, depending on the formulations tested.  The findings of this research offer a 318 
new mechanistic explanation of the large variability in oxycodone oral bioavailability.  For drug like 319 
oxycodone with high intrinsic clearance and high liver extraction ratio, its total body clearance is largely 320 
determined by the blood flow feeding into the metabolic enzymes.  When the rate of drug release from 321 
oral formulations is much slower than the intrinsic oxycodone clearance rate, the total body clearance of 322 
oxycodone is largely determined by the slow drug release rate from the formulations.  Therefore, 323 
different IR and ER formulations with distinct oxycodone release rates will cause different oxycodone 324 
total body clearance and significantly affect the first pass extraction and bioavailability of oxycodone  325 
(Table 5, 6, and 7 in the results).   326 
      327 
There was also considerable variation in the apparent volume of distribution and apparent total body 328 
clearance reported in the literature (Table 1).  The lack of concordance between the changes in apparent 329 
volume of distribution and apparent total body clearance were most puzzling and contradicted the 330 
traditional pharmacokinetic concept that route of drug administration should only affect a drug’s 331 
systemic bioavailability but  not affect its intrinsic distribution and dispositional characteristics.  The 332 
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mechanistic explanation on the discordant effect of different routes of oxycodone delivery on its 334 
apparent volume of distribution and apparent total body clearance.  The slower drug release rates from 335 
different IR and ER oral formulations and intranasal administrations causes slower effective oxycodone 336 
blood input rate and results in slower oxycodone total body clearance.  In addition to the different 337 
extent of first pass effect caused by slower oxycodone release from IR or ER oral formulations and 338 
intranasal administration, the slower oxycodone release also affected the fraction of dose absorbed and 339 
complicated the eventual systemic bioavailability of oxycodone.  While the route and rates of 340 
oxycodone delivery does not affect its distribution characteristics, the route and rate do affect the 341 
denominator but NOT the nominator on the estimation of apparent volume distribution in V/F.  342 
However, route and rate of oxycodone delivery directly changes oxycodone total body clearance rate 343 
and indirectly affect the fraction of oxycodone absorbed (Table 2), as such the total effect would be on 344 
both the nominator and denominator in estimation of apparent total body clearance in CL/F; 345 
consequently, apparent volume of distribution would become disparate from the apparent total body 346 
clearance estimation by traditional non-compartmental analyses and one-compartment analyses (Table 347 
1).  348 
Furthermore, different terminal half-lives from different oral formulations had been traditionally 349 
attributed to flip-flop kinetics, i.e. slower oral absorption reflected the terminal half-lives rather than the 350 
different oxycodone total body clearance as a result of slower absorption.  However, upon closer 351 
examination, the rate of oxycodone oral absorption based on non-compartmental or one-compartment 352 
analysis have invariably yielded a more rapid absorption rate constant than the elimination rate 353 
constant (Table 1).  Based on the findings of this research, the slower oxycodone input to liver portal 354 
vein affected slower oxycodone total body clearance but did not affect oxycodone distribution causing a 355 
shallower slope of terminal elimination phase (kel) by way of CL/V.  Thus, the terminal phase of 356 
oxycodone PK profile is a direct result of slower oxycodone total body clearance which is caused by 357 
slower oxycodone release.  Though the rate of oral oxycodone absorption in modified release 358 
formulations and extravascular delivery is still much faster than the rate of oxycodone total body 359 
clearance and would be not reflected in its terminal phase of oxycodone PK profile, the longer terminal 360 
elimination phase would actually reflects its slower total body clearance as a result of the slower 361 
oxycodone absorption. .  362 
Oral absorption of oxycodone is rapid, as reflected by large rate constant from the one- and two-363 
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with a rapid ascending oxycodone plasma concentration-time profile for immediate release and certain 365 
ER formulations (Table 2 and figure 2) when oxycodone release is fast.  However, when the rate of 366 
oxycodone release is modified and oxycodone is taken with food, the resulting convex and or sigmoid 367 
plasma-concentration-time during the absorption phase was better described with a time-varying 368 
Weibull absorption rate function (figure 3).  The Weibull function appeared to capture the dynamic 369 
time-varying nature of oxycodone better than the first-order release with a constant rate, and more 370 
likely reflected the physical dissolution and physiological conditions of GI track.       371 
The insights from this research shed new light on the strategy of modified release oxycodone 372 
development.  In the past, efforts have been directed to delay and slow oxycodone release in proximal 373 
intestine and increase distal intestinal absorption of oxycodone.  However, findings from this research 374 
indicate that distal intestinal absorption of oxycodone is poor and slow.  Compared to immediate 375 
release oxycodone, the elevation in plasma concentration of oxycodone following Cmax by modified 376 
release formulations is a product of slower oxycodone total body clearance and decreasing oxycodone 377 
absorption.  Rather than delaying release of oxycodone, optimization may be achieved by modifying the 378 
rate of oxycodone release in proximal intestine to maximize the fraction of oxycodone absorbed while 379 
slowing oxycodone total body clearance. 380 
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Figure Legends  490 
 491 
Figure 1. Mean plasma concentration–time profile of oxycodone from different doses, different 492 
types of formulations and different routes of extravascular administration. 493 
 494 
Figure 2. Mean plasma concentration–time profile of oxycodone from different doses under IV 495 
administration and goodness-of-fit of the two-compartment analyses of the IV data to assess the 496 
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Figure 3. Goodness-of-fit of the two-compartment analyses with first-order absorption rate 500 
constant and saturable elimination affected by slower drug input to portal vein for (a) controlled-release 501 
formulation from study 2, (b) immediate-release formulation from study 2, (c) once-a-day CR tablets 502 
from study 8, and (d) commercial products (bid) from study 8.  Observed: observed concentrations; 503 
IPRE: model predicted concentrations.  504 
 505 
Figure 4. Goodness-of-fit of the two-compartment analyses with first-order absorption rate 506 
constant or Weibull absorption and saturable elimination affected by slower drug input to portal vein 507 
for (a) IRO-A 5 mg fasted data, (b) IRO-A 10  mg fasted data, (c) IRO-A 15 mg fasted data, (d) IRO-A 15 508 
mg fed data, (e) IRO 15 mg fed data.  Observed: observed concentrations; IPRE (ka constant): model 509 
predicted concentrations with first-order absorption rate constant; IPRE (Weibull): model predicted 510 
concentrations with Weibull absorption. 511 
 512 
Figure 5. Goodness-of-fit of the two-compartment analyses with Weibull absorption and 513 
saturable elimination affected by slower drug input to portal vein under intranasal administration. 514 
Observed: observed concentrations; IPRE: model predicted concentrations. 515 
 516 
Figure 6. Goodness –of-fit of sensitivity analysis using one-compartment analyses with saturable 517 
elimination affected by slower drug input to portal vein in the absence of IV data for (a) controlled-518 
release formulation from study 2, (b) immediate-release formulation from study 2. Observed: observed 519 
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Tables 1 
Table 1: Summary of Clinical Studies Included in Meta-analysis 2 
Study Number Dose Type of Formulation Route of Administration 
1(Hao et al., 
2014) 
2.5, 5 and 10 mg Oxycodone hydrochloride solution IV 
2(Mandema et 
al., 1996) 
20 mg IR solution and CR tablet PO 
3(Kokki et al., 
2004) 
0.1 mg/kg Oxycodone hydrochloride solution IV, intramuscularly, and 
buccally 
4(Bass et al., 
2012) 
5, 10, and 15 mg An immediate-release oxycodone hydrochloride formulation (IRO-A) 
and marketed oxycodone hydrochloride (IRO) tablets 
PO 
5(Takala et al., 
1997) 
0.05 mg/kg Oxycodone hydrochloride solution IV and intranasal 
6(Kokubun et 
al., 2014) 
5 mg Oxycodone hydrochloride solution IV 
7(Mundin et 
al., 2012) 
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8(Kim et al., 
2015) 
10 and 20 mg IR and CR PO 
 3 
IV, intravenously; PO, orally; IR, immediate-release; CR, controlled-release; IRO, marketed oxycodone hydrochloride (IRO) tablets; IRO-A, An 4 
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Table 2: PK Parameter Estimates from Non-Compartmental Analyses 6 
Study Dose (mg) Formulation/Route t1/2 (hr) Vz/F (L) CL/F (L/hr) 
   Estimated Reported  Estimated Reported 
2 20 CR 8.42 7.99±2.96 1097.62 90.37  
2 20 IR 3.70 3.21±0.87 539.86 101.16  
4 5 IRO-A 5 mg fasted 3.24 3.24 479.12 102.40 105.48 
4 10 IRO-A 10 mg fasted 3.72 3.38 544.84 101.41 104.7 
4 15 IRO 15 mg fed 3.47 3.57 397.43 79.45 96.5 
4 15 IRO-A 15 mg fasted 3.25 3.71 459.23 97.80 81.5 
4 15 IRO-A 15 mg fed 5.25 3.74 603.92 79.66 79.3 
5 6.7 intranasal 5.58  794.83 98.72 114.2 
8 10 IR-bid 8.81  676.62 106.48 112.26 
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t1/2, terminal half life; Vz/F, terminal volume of distribution; CL/F, apparent total body clearance; CR, controlled-release; IR, immediate-release; 8 
IRO, marketed oxycodone hydrochloride (IRO) tablets; IRO-A, An immediate-release oxycodone hydrochloride formulation; bid, twice daily; qd, 9 
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Table 3: PK Parameter Estimates from One-Compartment Analyses 12 
Study Dose (mg) Formulation/Route Ka (1/hr) V/F (L) CL/F (L) 
2 20 CR 0.70 1120.3 88.8 
2 20 IR 2.99 540.6 102.6 
4 5 IRO-A 5 mg fasted 0.24 114.7 102.7 
4 10 IRO-A 10 mg fasted 0.22 97.2 101.4 
4 15 IRO-A 15 mg fasted 0.23 102.0 98.5 
4 15 IRO-A 15 mg fed 0.19 203.6 82.1 
4 15 IRO 15 mg fed 0.22 76.1 79.2 
5 6.7 intranasal 0.15 28.1 105.4 
8 10 IR-bid 0.08 73.3 77.4 
8 20 CR-qd  0.61 1521.9 73.5 
 13 
Ka, absorption rate constant; V/F, apparent volume of distribution; CL/F, apparent total body clearance; CR, controlled-release; IR, immediate-14 
release; IRO, marketed oxycodone hydrochloride (IRO) tablets; IRO-A, An immediate-release oxycodone hydrochloride formulation; bid, twice 15 
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Table 4: Intrinsic Oxycodone PK Parameter Estimates from IV Administration 19 
PK Parameters Mean 90% CI* 
V2 (L) 39.2 (22.3, 64.6) 
V3 (L) 105 (73.4, 143.9) 
Q (L/hr) 199 (89.3, 356.2) 
CLintrinsic (L/hr) 75.8 (49.4, 108.3) 
Qh (L/hr) 84 FIXED  
CL (L/hr) 39.8  
 20 
*: Nonparametric 90% CI (5 - 95 percentiles) from the 100 bootstrap; 21 
CI, confident interval; V2, volume of distribution of central compartment; V3, volume of distribution of 22 
peripheral compartment; Q, inter-compartment clearance; CLintrinsic, in vivo intrinsic clearance; Qh, the 23 
drug input rate into the blood flow feeding into clearance organ (portal liver blood flow for IV 24 
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Table 5: PK Parameter Estimates from Two-Compartment Analyses with First-Order Absorption Rate Constant and Saturable 27 















(L/hr) F1  
CL  
(L/hr) 
  IV 39 105 199 75.8   84   39.8 
2 CR/PO     0.348 22.7 20.4% 17.5 
2 IR/PO     1.34 54.7 33.6% 31.8 
8 CR (qd)/PO         0.477 7.4 9.0% 6.7 
8 
Commercial 
IR (bid)/PO         0.886 12.3 13.9% 10.6 
 29 
V2, volume of distribution of central compartment; V3, volume of distribution of peripheral compartment; Q, inter-compartment clearance; 30 
CLintrinsic, in vivo intrinsic clearance; Ka, absorption rate constant; Qh, the drug input rate into the blood flow feeding into clearance organ (portal 31 
liver blood flow for IV administration); F1, bioavailability; CL, clearance defined by Equation 2; IV, intravenous; CR, controlled-release; PO, orally; 32 
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Table 6: PK Parameter Estimates from Two-Compartment Analyses with Weibull Absorption and Saturable Elimination Affected 34 









(L/hr) そ  せ  
Qh  
(L/hr) F1  
CL  
(L/hr) 
  IV 39 105 199 75.8     84   39.8 
5 Intranasal     0.465 1.92 21.4 29.9% 16.7 
4 IRO-A 5mg fasted         0.878 3.64 31.0 34.9% 22.0 
4 IRO-A 10mg fasted     0.958 3.2 32.7 37.0% 22.8 
4 IRO-A 15mg fasted     0.806 3.86 29.5 35.1% 21.2 
4 IRO-A 15mg fed     2.21 2.68 26.6 40.1% 19.7 
4 IRO 15mg fed         0.833 4.03 26.6 39.7% 19.7 
 36 
V2, volume of distribution of central compartment; V3, volume of distribution of peripheral compartment; Q, inter-compartment clearance; 37 
CLintrinsic, in vivo intrinsic IlearanIe; ゜, ゜ faItor of WeiHull distriHution; ゛, ゛ faItor of WeiHull distriHution; Qh, the drug input rate into the blood 38 
flow feeding into clearance organ (portal liver blood flow for IV administration), F1, bioavailability; CL, clearance defined by Equation 2; IV, 39 
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Table 7: PK Parameter Estimates from Sensitivity Analysis 41 
 IR CR 
KA (1/hr) 2.99 0.698 
V (L) 541 541 
CL (L/hr) 103 42.8 
F1 (CR/IR) 1 48.3% 
 42 



































IRO 15 mg fed-15mg (study4)
IRO-A 10 mg fasted-10mg (study4)
IRO-A 15 mg fasted-15mg (study4)
IRO-A 15 mg fed-15mg (study4)
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